Royalty Report: Drugs, Central Nervous System, Diagnostic – Collection: 245927

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 6

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 6

Primary Industries

  • Drugs
  • Central Nervous System
  • Diagnostic
  • Drug Discovery
  • Cancer
  • Disease
  • HIV / AIDs

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 245927

License Grant
Licensor, a University, hereby grants to Company and its affiliates for the term (a) a royalty-bearing license under the Patent Rights to develop, make, have made, use, sell, offer to sell, lease, and import Licensed Products in the field in the territory and to develop and perform Licensed Processes in the field in the territory;  (b) a royalty-bearing license to use the tangible property to develop, make, have made, use, sell, offer to sell, lease and import Licensed Products in the field in the territory and to develop and perform Licensed Processes in the field in the territory.
License Property
Licensed Product shall mean any product or part thereof that: (i)  absent the license granted hereunder, would infringe one or more valid claims of the Patent Rights; or  (ii) is manufactured by using a Licensed Process or that, when used, practices a Licensed Process.

Patent Rights shall mean: (a) the United States and international patents listed.
US Patent Application #10/108,195 titled Methods and Products related to FGF Dimerization
(b) the United States and international patent applications and/or provisional applications listed and the resulting patents;  (c) any patent applications resulting from the provisional applications listed, and any divisionals, continuations, continuation-in-part applications, and continued prosecution applications (and their relevant international equivalents) of the patent applications listed and of such patent applications that result from the provisional applications listed, to the extent the claims are directed to subject matter specifically described in the patent applications listed, and the resulting patents;  (d) any patents resulting from reissues, reexaminations, or extensions (and their relevant international equivalents) of the patents described in (a), (b), and (c) above; and (e) international (non-United States) patent applications and provisional applications filed after the effective date and the relevant international equivalents to divisionals, continuations, continuation-in-part applications and continued prosecution applications of the patent applications to the extent the claims are directed to subject matter specifically described in the patents or patent applications referred to in (a), (b), (c), and (d) above, and the resulting patents.

Licensed Process shall mean any process that, absent the license granted hereunder, would infringe one or more valid claims of the Patent Rights or which uses a Licensed Product.

United States Patents and Applications
M.I.T. Case No. 9265
'A Novel Fibroblast Growth Factor Dimer'

International (non-U.S.) Patents and Applications
M.I.T. Case No. 9265
'A Novel Fibroblast Growth Factor Dimer'

WO Patent Application Serial No US02/09517, Filed on March 27, 2002
Entitled: METHODS AND PRODUCTS RELATED TO FGF DIMERIZATION

Field of Use
Field shall mean human therapeutics for the treatment of neurological disorders and conditions, which shall include disorders and conditions pertaining to the central nervous, peripheral nervous, autonomic nervous, and neuromuscular systems.

patents pertain to a novel molecule for treatment of neurological disorders, including stroke.

IPSCIO Record ID: 274908

License Grant
The German Licensor, a non-profit scientific research organisation, grants to Israeli Company during the Term a co-exclusive, worldwide, royalty-bearing license under the MPG Patent Rights to develop, have developed, make, have made, use, have used, import, have imported, sell and have sold Licensed Products, and to perform, have performed, sell and have sold Licensed Services, each in the Field.

In order to establish co-exclusivity, Licensor shall not grant, during the Term, more than three other co-exclusive licenses to the MPG Patent Rights in the Field with the scope as set forth (hereinafter the “Other Diagnostic Licenses”, or the 'Other Diagnostic Licensees', as applicable).

License Property
The license is to use its microRNAs, including approximately 110 biologically validated human microRNAs, for diagnostic applications.

Licensed Products shall mean any product (I) that, or the development, manufacture, use or sale of which, absent the license granted hereunder, would infringe one or more Pending Claims or Valid Claims of the MPG Patent Rights, or (ii) which is developed or manufactured by using a Licensed Process or that, when used, practices a Licensed Process.

MPG Patent Rights shall mean:  (Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V. (hereinafter “MPG“), a German non-profit scientific research organisation)
(a)  
the patent applications filed by MPG listed, and the resulting patents,
(b)  
any subsequent patent applications in any jurisdiction claiming the same priority date and directed to the same subject matter as the patent application listed, and any divisionals, continuations, continuation-in-part applications, and continued prosecution applications (and their relevant international equivalents) of the patent applications listed, and the resulting patents, and
(c)  
any patents resulting from reissues, reexaminations (and their relevant international equivalents) of the patents described in (a) and (b) above.
International Patent applications filed by MPG entitled 'Small expressed RNA molecules (MicroRNA molecules)'

Licensed Service shall mean any service (I) that, or the performance or sale of which, absent the license granted hereunder, would infringe one or more Pending Claims or Valid Claims of the MPG Patent Rights, or (ii) which, when performed, uses a Licensed Process or a Licensed Product.

Field of Use
Field shall mean sale and use of Licensed Products, or performance and sale of Licensed Services, for:
(a) Companys internal and collaborative research and development purposes, and
(b) Diagnostic Purposes, specifically excluding any sale and use of Licensed Products, or performance and sale of Licensed Services, for Research Purposes or for Therapeutic Purposes.

IPSCIO Record ID: 299252

License Grant
Licensor, a medical college, hereby grants Licensee an exclusive right and license to Licensor’s rights to make, use, and Sell Licensed Products for the Field of Use in the Licensed Territory during the term of this Agreement.
License Property
Licensed Product(s) shall mean any process, service, or product, the manufacture, use, or sale of which is covered by a Valid Claim or incorporates or uses any Licensed Technology.

Licensed Technology shall mean all information and materials proprietary to Licensor, including designs, technical information, know how, knowledge, data, specifications, test results and other information relating to the Licensed Patents and disclosed by Licensor to Licensee on the date of this Agreement or during the term hereof.

Licensed Patents shall mean the inventions embodied in the patent applications and patents identified in hereof, together with all divisionals, continuations, reissues, and foreign counterparts of such applications or patents.

Licensor holds certain title and rights in a joint invention on the alpha 7 nicotinic receptor agonists and the JAK pathway with Licensee, specifically:

Case #016-02: 'Methods and Compositions for Treatment of Central Nervous System Disorders'
Patent Status: Provisional U.S. patent application prepared by Licensee, complete with data and claims.

Field of Use
License relates to a patent covering a method of use of a substance that stimulates the activity of nicotinic acetylcholine receptors by inhibiting the activity of another class of receptors, a method of use of increasing the presence of a therapeutic substance to treat neurodegeneration and a screening method.

Neurodegeneration refers to the progressive atrophy and loss of function of neurons, which is present in neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

IPSCIO Record ID: 273247

License Grant
The Israeli Licensor, the technology transfer company of the University, hereby grants to the Company an exclusive or non-exclusive license, in accordance with the Agreement terms, in the Territory, with the right to grant sublicenses as provided, to practice and utilize the Licensed Patent Rights, and the Licensed Know-how to (a) research and develop products and services solely in the Field of Use, and (b) to register, make, have made, lease, use, import, market, have marketed, and/or sell or have sold products and services solely in the Field of Use.
License Property
Product(s) shall mean any products, product component, production supplement and/or process covered by a valid claim of the Licensed Patent Rights in the country where the product is sold and/or that embodies any Licensed Know-How.

Licensed Patent Rights shall mean the Patent Rights, the Non-exclusive Patent Rights and Research Patent Rights.  

Research Patent Rights shall mean any United States and/or non-United States patent or patent applications and all substitutions, divisions,  continuations, continuations-in-part, reissues, reexaminations and extensions  thereof that are owned or otherwise controlled by the Licensor and that cover the Know-how and/or Research Know-how developed prior to or during the course of the Research Program.

Patent Rights shall mean:  The patent application set forth, designated as exclusive; Any non-United States patent applications claiming  priority from the patent application referred to; Claims of United States continuation-in-part applications, and of the resulting patents; and Any reissues, divisionals, amendments or extensions of the United States or non-United States patents.

Exclusive Patent Rights:  New Heterocyclic compounds, method of developing new drug leads and combinatorial libraries used in such method.
Non-exclusive Patent Rights:  A general procedure for the preperative scale systhesis of protected Ca (functionalysed alkyl) amino acids suitable for solid phase synthesis.

Exclusive Know-How: All new developments, now in existence or to be developed pursuant to the Research Program.

Non-Exclusive Know-How: The novel building units described in Agreement and a process for the preparation of compounds described in the Agreement consisting of a multistep reaction procedure.

Non-Exclusive Patent Rights shall mean the provisional patent application set forth in this Agreement designated as non-exclusive; Any United States  utility patent application and non-United States patent applications based, in whole or in part, on the provisional patent application set forth; The United States and non-United States patents issued from the applications referred to; Claims of United States continuation-in-part applications, and of the resulting patents, which are based on the subject matter specifically described; and Any reissues, divisionals, amendments or extensions of the United States or non-United States patents described.

Field of Use
This invention is in the field of using combinatorial chemistry to develop new drugs.

IPSCIO Record ID: 282853

License Grant
Hospital hereby grants Licensee (a) an exclusive, worldwide, royalty-bearing license  to all of its interests  in, to, and under Licensed Patents to import, make, have made, use, have used, offer for sale and sell Products; (b) to the extent an exclusive license is not available to Licensee in a particular country because of government action in that country a non-exclusive, royalty bearing license to all of HospitalS interests in, to, and under the Licensed Patents  to import, make, use, offer for sale and sell Products;  (c) the right to grant sublicenses  under the Licensed Patents exclusively licensed to Licensee.
License Property
The term Licensed Patents shall mean the patent applications listed hereto and the non-U.S. equivalents of such applications, including any utility patent application based on any provisional application included in Licensed Patents, and any division, continuation or any Letters Patent or the equivalent thereof issuing thereon or reissue, reexamination or extension thereof.  Licensed Patents shall also include those claims in any continuation-in-part of the aforementioned patent applications owned, controlled, or available for license from the Hospital,  which claims an invention described or claimed in said patent application.

U.S. Patent Applications Ser. No. 08/263,607, filed June 20, 1994, Ser. Nos. 08/458,061 and 08/458,085, both filed June 1, 1995, all  entitled 'Administration of Pirenzipine, Methyl Scopolamine, and Other Muscarinic Receptor Antagonists for Treatment of Lipid Metabolism Disorders'
U.S. Patent Applications Ser. No. 08/271, 881, filed July 7, 1994, Ser. Nos. 08/458,960 and 08/459,114, both filed June 2, 1995, all entitled 'Method of Regulating Immune Function'
U.S. Patent Application Ser. No. 08/475,296, filed June 7, 1995,  entitled 'Method of Inhibiting Neoplastic Disease in Mammals'
U.S. Provisional Patent Application Ser. No. 60/001,428, filed July 25, 1995, entitled 'Neuroendocrine Therapy for Inhibiting Neoplastic Disease'

The term Product shall mean any article, device, composition, method or service, the importation,  manufacture, use, offer for sale or sale of which, absent the licenses granted herein, would infringe an enforceable claim of any Licensed Patent.

Field of Use
This agreement pertains to the drug industry relating to inventions pertaining to the administration of muscarinic receptor antagonists, certain enzyme inhibitors,  a method of regulating immune function, and methods of treating neoplastic disease.

Neoplastic diseases are conditions that cause tumor growth — both benign and malignant. Benign tumors are noncancerous growths. They usually grow slowly and can't spread to other tissues.

IPSCIO Record ID: 227262

License Grant
Licensor, a University, hereby grants to Licensee and its Affiliates an exclusive, royalty-bearing license, with the right to grant sublicenses, under the Licensed Intellectual Property, to Develop and Commercialize Licensed Products in the Territory.
License Property
Licensed Product means a diagnostic, prophylactic or therapeutic drug product the Development, Commercialization or other use of which is Covered by a Valid Claim of any of the Licensed Patent Rights in the country where such product is manufactured, used, sold or imported.

Licensed Patent Rights means (a) the patent applications set forth, (b) United States patents issued from the applications listed and from divisionals and continuations of these applications and any reissues of such United States patents, (c) claims of continuation-in-part applications and patents directed to subject matter specifically described in the applications listed, and (d) claims of all foreign patent applications, patents, and other intellectual property which are directed to the subject matter specifically described in the United States patents and/or patent applications listed.

Certain Licensed Patent Rights include:
1. United States provisional patent application no. 60/374,557 filed on April 22, 2002 entitled 'Atomic Coordinates (3D Structure) of the N-Terminal Portion of the Immature HIV-1 Gag Polyprotein' (attorney docket no. UMBC2392MS):

2. United States provisional patent application no. 60/375,852 filed on April 25, 2002 entitled 'Atomic Coordinates (3D Structure) of the N-Terminal Portion of the Immature HIV-1 Gag Polyprotein' <attorney docket no. UMBC2392MS-2): and

3. United States provisional patent application no. 60/404,043 filed on August 16, 2002 entitled 'Method of Identifying Anti-Viral Compounds' <attorney docket no.
UMBC2398MS).

Licensed Intellectual Property means Licensed Know-How and Licensed Patent Rights.

Field of Use
This agreement pertains to the drug relating to HIV disease.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.